Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label etravirine study in treatment-experienced children and adolescents with HIV-1
NL-OMON31931Phase 2Not yet recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of etravirine in Human immunodeficiency virus infection type 1, sponsored by Janssen Pharmaceutical. Primary endpoint: Long-term safety and tolerability. Planned start Sep 2008; status: not yet recruiting.
02
Drugs
etravirine
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON31931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31931.